Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [4117]

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell...

Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma ( Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK )

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in...

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer...

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )

Part 1: Why test?

Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain

Part 1: Why test? ( Dr Elena Castro - Hospital Universitario 12 de Octubre, Madrid, Spain )

Part 2: How to get biopsies for testing?

Dr Lynda Corrigan and Dr Stephen Finn

Part 2: How to get biopsies for testing? ( Dr Lynda Corrigan and Dr Stephen Finn )

Part 3: Managing testing efficiencies – How to optimise next generation...

Prof Eva Compérat - Medical University of Vienna, Vienna, Austria

Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing ( Prof Eva Compérat - Medical University of Vienna, Vienna, Austria )

Part 4: Clinical decision making - Interpretation of next generation sequencing...

Prof Gunhild von Amsberg and Prof Eva Compérat

Part 4: Clinical decision making - Interpretation of next generation sequencing results ( Prof Gunhild von Amsberg and Prof Eva Compérat )

Screen-detectable cancers account for majority of early-onset cancer cases...

Prof Aldenise Ewing - The Ohio State University, Colombus, USA

Screen-detectable cancers account for majority of early-onset cancer cases under age 50 ( Prof Aldenise Ewing - The Ohio State University, Colombus, USA )

Perioperative anti–PD-L1 therapy improves event-free survival in resectable...

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )

Machine learning models improve prediction of immunotherapy outcomes across...

Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types ( Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA )

Denikitug shows immune activation and early anti-tumour activity in advanced...

Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour ( Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA )

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

More from ecancer